The Minister in charge of emergency housing says he stands by decisions to tighten eligibility criteria for those in need, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that British Columbia, ...

Terns' lead candidate TERN-701 is an investigational oral allosteric BCR:ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at ...

MSD will likely experience strong selling pressure in the coming months because of the new geopolitical risks. Click here to ...

MSD/Merck & Co's headquarters in Rahway, New Jersey. MSD has said it plans to separate its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31 ...

Negotiations between MSD and Revolution Medicines over a possible takeover – estimated to have been potentially worth up to $30 billion – have reportedly ended without agreement. That is according to ...

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for Merck’s WINREVAIR in Adults With CpcPH-HFpEF ...

Citi has poached Ben Bartholomaeus from Goldman Sachs as its head of healthcare advisory for Australia and New Zealand. Citi ...

Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies ...